within Pharmacolibrary.Drugs.ATC.L;

model L01EG03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.275,
    Cl             = 0.00019,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.172,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.17,
    k12             = 14.8,
    k21             = 14.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EG03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ridaforolimus is an oral mTOR inhibitor developed as an anticancer agent, primarily for the treatment of sarcomas and other solid tumors. It is not currently approved for clinical use by the FDA or EMA, but has been investigated in multiple clinical trials.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced solid tumors or sarcomas following oral administration of ridaforolimus.</p><h4>References</h4><ol><li><p>Pearson, AD, et al., &amp; Geoerger, B (2016). A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. <i>Oncotarget</i> 7(51) 84736–84747. DOI:<a href=\"https://doi.org/10.18632/oncotarget.12450\">10.18632/oncotarget.12450</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27713169/\">https://pubmed.ncbi.nlm.nih.gov/27713169</a></p></li><li><p>Stroh, M, et al., &amp; Agrawal, N (2014). Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation. <i>Journal of clinical pharmacology</i> 54(11) 1256–1262. DOI:<a href=\"https://doi.org/10.1002/jcph.331\">10.1002/jcph.331</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24827931/\">https://pubmed.ncbi.nlm.nih.gov/24827931</a></p></li><li><p>Seki, Y, et al., &amp; Tamura, T (2012). Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 69(4) 1099–1105. DOI:<a href=\"https://doi.org/10.1007/s00280-011-1788-4\">10.1007/s00280-011-1788-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22143378/\">https://pubmed.ncbi.nlm.nih.gov/22143378</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EG03;
